Predicting hemorrhagic transformation and its timing from maximum cerebral lesion diameter in nonlacunar ischemic strokes.


Journal

Brain and behavior
ISSN: 2162-3279
Titre abrégé: Brain Behav
Pays: United States
ID NLM: 101570837

Informations de publication

Date de publication:
01 2020
Historique:
received: 02 05 2019
revised: 29 10 2019
accepted: 22 11 2019
pubmed: 18 12 2019
medline: 5 1 2021
entrez: 18 12 2019
Statut: ppublish

Résumé

We performed this retrospective cohort study to establish which factors are mostly indicative of the appearance of hemorrhagic transformation (HT) and of its time course in a sample of nonlacunar ischemic strokes. In 402 patients with nonlacunar ischemic stroke (75.0 ± 12.7 years, 192 male), clinical, laboratory, and neuroimaging variables obtained during the first 3 days of hospitalization were compared between patients with and without HT at computer tomography scan. HT was documented in 129 patients (32.1%), including 36 with parenchymal hematoma (PH), after a median time of 6 days (range 1-27). Many variables were univariately associated with HT, but only 5 of them were confirmed in Cox regression (Hazard Ratio, 95% Confidence Interval): maximum cerebral lesion diameter (CLD) in cm (1.12, 1.06-1.18; p = .0001), hemoglobin in g/dl (1.16, 1.06-1.27; p = .002), blood glucose in mmol/L (1.10, 1.03-1.18; p = .007), prior anticoagulant therapy (1.82, 1.10-3.03; p = .02), and edema with mass effect (1.72, 1.08-2.75; p = .02). Thus, the most significant predictor was CLD. The overall risk of HT was minimum for CLD < 2 cm (1.5%), intermediate for CLD ≥ 2 and < 5 cm (22%), and maximum for CLD ≥ 5 cm (58%). The residual probability of having HT decreased progressively over time, and a simple formula is proposed to predict, from CLD in cm, when the probability of HT falls below 10%. The main determinant of HT was CLD, a simple quantitative parameter that could prove useful, in particular, in deciding the timing of anticoagulation in cardioembolic stroke patients.

Identifiants

pubmed: 31846215
doi: 10.1002/brb3.1497
pmc: PMC6955832
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e01497

Informations de copyright

© 2019 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.

Références

Stroke. 2014 Mar;45(3):752-8
pubmed: 24473180
Lancet. 1991 Jun 22;337(8756):1521-6
pubmed: 1675378
Ann Neurol. 2012 Nov;72(5):799-806
pubmed: 23280795
Stroke. 2015 Aug;46(8):2175-82
pubmed: 26130094
Eur J Neurol. 2013 Jun;20(6):962-7
pubmed: 23521544
Cell Biochem Biophys. 2014 Sep;70(1):135-42
pubmed: 24691925
Eur J Neurol. 2015 Jul;22(7):1048-55
pubmed: 25319957
Cerebrovasc Dis. 2004;18(4):304-11
pubmed: 15331877
Neurol Res. 2016 Jun;38(6):538-44
pubmed: 27320249
Expert Rev Hematol. 2016 Sep;9(9):891-901
pubmed: 27367035
J Stroke Cerebrovasc Dis. 2004 Nov-Dec;13(6):235-46
pubmed: 17903981
Acta Neurochir (Wien). 2007 Jan;149(1):1-10
pubmed: 17151832
Biochim Biophys Acta. 2004 Jun 11;1672(3):203-13
pubmed: 15182940
Circ Cardiovasc Qual Outcomes. 2015 Jul;8(4):413-20
pubmed: 26152682
Brain Behav. 2020 Jan;10(1):e01497
pubmed: 31846215
J Am Heart Assoc. 2017 Nov 29;6(12):
pubmed: 29220330
Stroke. 1999 Nov;30(11):2347-54
pubmed: 10548669
AJNR Am J Neuroradiol. 2007 Aug;28(7):1292-8
pubmed: 17698530
Conf Proc IEEE Eng Med Biol Soc. 2006;2006:1881-4
pubmed: 17946485
Lancet. 1974 Jul 13;2(7872):81-4
pubmed: 4136544
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Stroke. 1999 Nov;30(11):2280-4
pubmed: 10548658
BMC Neurol. 2017 Sep 7;17(1):177
pubmed: 28882130
Medicine (Baltimore). 2016 Jan;95(2):e2430
pubmed: 26765425
JACC Cardiovasc Interv. 2018 Oct 22;11(20):2072-2080
pubmed: 30268874
Cerebrovasc Dis. 2005;19(2):117-24
pubmed: 15640606
J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1080-3
pubmed: 2292703
Dev Neurosci. 2005 Mar-Aug;27(2-4):87-92
pubmed: 16046841
Stroke. 2002 Jul;33(7):1934-42
pubmed: 12105379
Am J Physiol Cell Physiol. 2001 Apr;280(4):C719-41
pubmed: 11245588
Eur Neurol. 2010;64(4):193-200
pubmed: 20714158
Stroke. 2018 Mar;49(3):e46-e110
pubmed: 29367334
Thromb Haemost. 2016 Aug 30;116(3):410-6
pubmed: 27346426
Eur Heart J. 2010 Oct;31(19):2369-429
pubmed: 20802247
Cerebrovasc Dis. 2011;32(4):334-41
pubmed: 21921596
JAMA Neurol. 2017 Oct 1;74(10):1174-1175
pubmed: 28892535
Eur J Neurol. 2006 Nov;13(11):1251-5
pubmed: 17038041
Cerebrovasc Dis. 2009;28(2):119-23
pubmed: 19506370
Trials. 2017 Dec 02;18(1):581
pubmed: 29197413
Cerebrovasc Dis. 2011;32(3):234-8
pubmed: 21860236
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Int J Cardiol. 2002 Nov;86(1):41-59
pubmed: 12243849
Stroke. 1997 May;28(5):957-60
pubmed: 9158632
Cerebrovasc Dis. 2013;35(1):53-9
pubmed: 23428997
Stroke. 2008 Aug;39(8):2249-56
pubmed: 18535273

Auteurs

Antonio Muscari (A)

Stroke Unit, Medical Department of Continuity of Care and Disability, S.Orsola-Malpighi Hospital, Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Luca Faccioli (L)

Diagnostic and Interventional Neuroradiology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy.

Maria Vittoria Lega (MV)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Andrea Lorusso (A)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Marco Masetti (M)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Marco Pastore Trossello (M)

Diagnostic and Interventional Neuroradiology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy.

Giovanni M Puddu (GM)

Stroke Unit, Medical Department of Continuity of Care and Disability, S.Orsola-Malpighi Hospital, Bologna, Italy.

Luca Spinardi (L)

Diagnostic and Interventional Neuroradiology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy.

Marco Zoli (M)

Stroke Unit, Medical Department of Continuity of Care and Disability, S.Orsola-Malpighi Hospital, Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH